Written reply to Parliamentary Question on moving critical illness policy definitions towards underlying disease and severity
AI Analysis
MAS has stated that the Life Insurance Association Singapore (LIA) will begin its next review of severe-stage critical illness definitions in 2027, examining whether selected definitions can rely less on specified procedures and more on the underlying disease and its severity. The announcement is a policy signal rather than an immediate rule change: any revised definitions are expected to affect new products only, with premiums potentially changing because broader or different claim triggers alter expected claims probability.
Key dates
- 2026-10-07
- MAS published its written parliamentary reply stating that LIA’s next review of severe-stage critical illness definitions will commence in 2027 and that updated definitions will apply to new products sold.
- 2027-01-01
- The LIA review is expected to commence during 2027; the publication does not specify an exact commencement date or impose a firm for firms to act by this date.
- 2025-10-01
- The LIA Critical Illness Framework 2024 was required to be adopted for new products no later than this date, according to independent industry and LIA-related materials; this is relevant background rather than a new deadline created by the MAS reply.
Suggested considerations
- Compliance teams may wish to monitor the LIA’s 2027 review, consultation materials, final framework amendments, implementation dates, and any MAS communications that follow.
- Insurers should consider mapping current severe-stage definitions to the procedures and clinical severity criteria that may be affected, including identifying products whose claims triggers are particularly dependent on a named surgical procedure.
- Product governance, actuarial, underwriting, claims, legal, and compliance functions may wish to assess how alternative disease- and severity-based triggers could affect coverage scope, expected claims frequency, reserves, reinsurance, and pricing.
- Firms should consider documenting whether existing policy wordings can continue to be administered consistently with their contractual terms and should avoid treating any future framework revision as automatically applicable to in-force policies.
- Insurers developing new products should consider preparing customer disclosures explaining the relevant disease, severity, diagnostic evidence, exclusions, waiting periods, and any procedure-independent claims criteria.
- Compliance teams may wish to review product approval and change-control processes so that future LIA definition changes are reflected consistently in policy documents, benefit illustrations, sales materials, claims manuals, staff training, and complaint-handling procedures.
- Actuarial and product teams should consider reassessing premiums and claims assumptions before launching products using revised definitions, since MAS expressly notes that premiums depend on the probability of claims materialising.
What changed
No immediate statutory requirement, product withdrawal, or mandatory amendment to existing policies was introduced. LIA’s 2027 review will consider procedure-neutral or less procedure-dependent definitions for certain medical conditions, while retaining the use of procedures where they provide objective evidence of severity, recovery duration, and financial impact. Any resulting changes will apply to new products sold; existing policies remain governed by their contractual definitions and terms. Independent industry reporting on the prior framework review indicates that the LIA’s standard definitions cover 37 severe-stage conditions and that the 2024 framework took effect for new products no later than 2025-10-01, reinforcing that periodic framework revisions are implemented prospectively
Compliance impact
The immediate compliance impact is low because the reply creates no binding amendment to policy contracts and does not require changes to products currently in force. The prospective changes could nevertheless have material conduct, product-governance, claims, actuarial, pricing, disclosure, and administration consequences if disease- and severity-based definitions broaden or otherwise change elig
Who is affected
Related regulations
References
AI-generated analysis. May contain errors or omissions — verify with the original MAS source before acting. Full disclaimer.
What the MAS said
Written reply to Parliamentary Question on moving critical illness policy definitions towards underlying disease and severity.
Published by MAS . Read the full notice at the source for the authoritative text.